Table 3.

Difference in clinical characteristics of responders and non-responders at baseline

Characteristics	Non-responders N = 32	Responders N = 27
Demographics
Age (years)	52±14	53±14
Male (%)	20 (63)	17 (63)
Baseline disease scores
Swollen joint count	5 (3–8)	3 (2–5)
Tender joint count	6 (3–10)	4 (2–7)*
PASI	2.6 (1.1–6.5)	1.8 (0.4–3.6)
Pain VAS	54±24	40±30*
Global VAS	57±28	40±24*
LEI >0 (%)	9 (28)	14 (54)*
HAQ total score	0.6 (0.4–1.1)	0.4 (0.1–0.8)*

Results shown as mean±SD, n (%) or median (IQR).

Non-responders: patients who were not continuously using MTX or were neither in MDA or EULAR definition of low disease activity at 6 months. Responders: patients who reached MDA and EULAR definition of low disease activity at 6 and 12 months on MTX monotherapy.

*p<0.05.

HAQ, Health Assessment Questionnaire; LEI, Leeds Enthesitis Index; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; VAS, Visual Analogue Scale.